Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint Of Progression-Free Survival For Patients With Pretreated KRASG12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb (BMY) announced positive results from the Phase 3 KRYSTAL-12 study of KRAZATI (adagrasib) for treating KRASG12C-mutated non-small cell lung cancer, meeting primary and key secondary endpoints. The study showed significant benefits in progression-free survival and overall response rate, with safety data consistent with known profiles. KRAZATI has received FDA accelerated approval and is under review for additional indications.
March 28, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's KRAZATI met primary and key secondary endpoints in a Phase 3 study for treating KRASG12C-mutated non-small cell lung cancer, showing significant benefits and consistent safety data.
Positive trial results typically lead to increased investor confidence, potentially boosting stock prices. The successful trial and FDA accelerated approval for KRAZATI position BMY favorably in the oncology market, likely leading to positive short-term stock movement.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100